What is BioScale?
Operating as a high-complexity CLIA laboratory, BioScale provides essential protein assay development and testing services that bridge the gap between advanced research and clinical application. The company is perhaps best known for its FDA-cleared Presage ST2 Assay, a vital tool for the prognosis of chronic heart failure. Beyond its proprietary diagnostic offerings, BioScale delivers comprehensive immuno and protein assay solutions tailored for hospitals, medical centers, and large-scale biotech enterprises. Their operational model emphasizes flexible, high-quality execution across diverse therapeutic areas, ensuring that clinical partners receive precise biomarker data necessary for informed medical decision-making and drug development efficacy.
How much funding has BioScale raised?
BioScale has raised a total of $116.2M across 5 funding rounds:
Series B
$3M
Series C
$20.7M
Series D
$25M
Unspecified
$18.8M
Series A
$48.7M
Series B (2005): $3M, investors not publicly disclosed
Series C (2007): $20.7M led by F2 Ventures and Blackfin Technology
Series D (2010): $25M, investors not publicly disclosed
Unspecified (2013): $18.8M featuring Morningside Group, New Science Ventures, and WFD VENTURES
Series A (2013): $48.7M backed by New Science Ventures newscienceventures.com and Morningside Ventures morningside.com
Key Investors in BioScale
New Science Ventures
A venture capital firm specializing in early and late-stage life sciences and information technology, focusing on companies that utilize novel scientific approaches to address unmet market needs.
WFD VENTURES
An investment firm providing equity financing and deep industry expertise specifically to medical device and healthcare technology companies to improve clinical outcomes.
F2 Ventures
A healthcare-focused investment platform that targets strategic arbitrage opportunities within the biotech sector to maximize innovation impact.
What's next for BioScale?
With the successful closure of this major enterprise-level funding round, BioScale is well-positioned to accelerate its commercial expansion and deepen its investment in next-generation diagnostic technologies. The company's strategic roadmap likely involves scaling its laboratory capacity to meet the rising demand for specialized protein biomarker analysis while simultaneously exploring new therapeutic indications for its existing assay portfolio. By maintaining its focus on high-complexity testing and clinical excellence, BioScale is poised to capture additional market share within the competitive diagnostics landscape, further cementing its role as a cornerstone of modern precision medicine.
See full BioScale company page
